Notice regarding Differences in the Non-consolidated Financial Results between the Fiscal Year Ended March 31, 2022 and the Previous Fiscal Year
Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, and Chief Executive Officer, Gyo Sagara; “ONO”) today announced that there were differences in the non-consolidated financial results (Japanese standard) between the fiscal year ended March 2022 (April 1, 2021 to March 31, 2022) and previous fiscal year.
- Differences in the full-year non-consolidated financial results between the fiscal year ended March 2022 and the previous fiscal year
(Unit: Millions of yen, except basic earnings per share)
for the year
(FY ended March 2021)
305,183 84,929 86,778 76,927 154.10 Actual Results(B)
(FY ended March 2022)
357,023 119,899 121,057 94,594 190.51 Change（B－A） 51,840 34,970 34,279 17,667 - Change（％） 17.0 41.2 39.5 23.0 -
- Reasons for the differences
Because of the growth in sales of main products such as Opdivo Intravenous Infusion for malignant tumors, and Forxiga Tablets for diabetes, chronic heart failure and chronic kidney disease, etc., as well as an increase in royalty revenue, there were differences in the full-year non-consolidated financial results between the fiscal year ended March 31, 2022 and the previous fiscal year.